The subject of the manuscript is important, significant and informative for complement researchers. However, I am not in favor of publishing this manuscript in such high impact journal as EMBO because I have two problems with this manuscript. 1. Table 1 presents the resolution of the diffraction data and it is at best 4.5Å or much less for both structures. The quality of the diffraction data is poor, with Rsym around 80% in last resolution shell. The average individual B-factors are close to 200 and only ~75% main chain torsions are in favorable regions. Interestingly, the cell dimensions are given up to second decimal, and glycans with individual B-factors around 300 are also placed in the density. The authors are overly optimistic (to put it mildly), where even the typical electron density map presented (normally drawn for the best defined protein segments) is of very low resolution, barely defining the surface and not even big side chains like HIS857 are clear. Hence, the conclusions drawn, the interactions described, the models built for other convertases and the paradigms defined for all convertase interactions are far more than one can expect from a structure determined at 5 to 4.5Å resolution. There is no mention of the resolution limits; neither in the abstract nor in the introduction and also findings and conclusions are not summarized in both places. One expects, the significance of the results after describing the findings, in the end of abstract and introduction and not a statement like 'the C5-CVF structure provides a structural framework for the design of selective inhibitors of complement activation", which is a stretch.
2. The authors state that there are no conformational changes in CVF upon binding to C5. I see the assertion that "the assignment of regions and even residues in contact across the C5-CVF interface can be carried out with confidence, since movements of domains and large conformational changes in loop regions compared to the starting models" can be identified. What is the starting model of CVF? It is the structure of CVF extracted from another complex. All models are built, compared and analyzed for conformational changes with a starting model other than the native apo-structure. It defies the logic when a published apo-CVF structure is available in PDB, authors do not compare before asserting that there are no conformational changes upon binding to C5. Is it enough to say that C3b and C4b look like CVF, and hence will have similar conformational changes (or lack of) upon binding to C5? In many places the text is confusing and no rms deviations are given for any structure superposed on another before proceeding with a discussion of similarities and their interactions with another complex macromolecule. The figures are clear and informative.
Referee #2 (Remarks to the Author):
Laursen et al., in their manuscript "Substrate recognition by complement convertases revealed in the C5-CVF complex" present crystals the structure of C5 in complex with CVF and the structure of a ternary complex between C5,CVF and SSL7, a complement inhibitor from S. aureus. Despite the low resolution of the structures, the complexes plausibly show how CVF recognizes its substrate C5, and in light of high sequence and structural conservation, this model is likely valid for all C3/C5 convertases of the classical and the alternative pathway. The work is solid; in fact the statistics are better than to be expected for 4.2Å structures. The paper is generally well written, yet not easy to comprehend as important points in the article are sometimes lost in the detailed descriptions.
Concerns:
In the abstract the authors imply that Bb has no role in substrate binding. This statement should be rephrased or supported by e.g a comparison of the binding affinities of C3-CVF and C3-CVFBb (catalytically inactive).
The authors decided to include the structure of the SSL7 complex in the manuscript. In my opinion this structure in the current version of the manuscript does not add much to the story. The structure is not mentioned in the discussion and SSL7 is only mentioned in passing in the introduction. If this structure remains in the manuscript I would hope to hear more about SSL7 and the implication of the complex in the discussion. Minor point: please add SSL7 to figure S6.
Discussion: In the section the "CP C5 convertase" the authors speculate on the structure of the classical C5 convertase although their structure does not contain any component of either the AP or CP convertase. They quote the findings of Vogt et al. (1978) , however these results should be treated with caution. An incorrect conclusion of this paper was that C3b alone is responsible for C5 cleavage, and that factor B competes with C5 binding. Addition of factor B could affect the assay in many ways, for example by reducing the excess of C3b required for C5 convertase activity. The discussion on the role of the 2nd C3b molecule in the C5 convertases could be moved from the supplement to the main part. The section "perspective for the development of complement inhibitors" does not really offer a perspective and lacks concrete ideas.
Minor points: P.11 last paragraph: C4b does not recognize C5. The manuscript describes two intriguing crystal structures for the complex between complement C5 and cobra venom factor, and that including SSL7. This potentially provides new insight into how complement activation can be inhibited by CVF, and the role of SSL7 in this. The manuscript appears suitable for EMBO Journal.
However the manuscript is a hard read and this is because there are issues of presentation. The authors need to go through their manuscript more carefully for clarity and readability to check that the general reader can see what the authors' points are and what the novelty is.
Major points
(1) The abstract needs rewriting in order to bring out the novelty of the study -it only makes general points. For example, the abstract does not make it clear that two crystal structures have been reported in this study. The abstract should make clearer that CVF binding induces a conformational change in C5 (if this is what the authors are saying), and what this implies for function, and likewise summarize the main result from the SSL7 co-crystal structure which is not even mentioned.
(2) There are two major conformations for these C3-type proteins -and they differ primarily in the TED (C5d) and CUB domain positions, plus a series of other conformational changes in the MG domains. The manuscript does not make clear for the general reader whether the changes in C5 resemble the C3 or C3b structure the closest (top page 6), or even an intermediate one for C3u or C3(H2O) that was presented at the complement New York meeting that is probably now published. Referee #1 (Remarks to the Author): Response: We have used the criterion of I/sigmaI > 2 for the outer shell for selection of the resolution limit of 4.2 Å. In response to the concerns raised by the reviewer, we have now cut the limit at the resolution to 4.3 Å, and present a breakdown-by-resolution table for data scaling and refinement in the new supplementary tables I and II, which we believe is sufficient to convince the reader that 4.3 Å is a reasonable resolution. Since the original submission we have also improved the structure of SSL7-C5-CVF significantly and at 4.3 Å resolution, the two structure now have Rfree of 26%, which is quite favorable at this resolution, as also noted by reviewer 2 below.
The displayed electron density maps shown in the original MS are omit 2mFo-DFc maps, and they are non-averaged, and therefore of course not as strong as possible, but they serve the purpose of convincing the reader that we can certainly detect conformational changes compared to the input models. The reviewer assumes that these are in the best regions of the structure, but this is certainly not true. The hairpin loop in fig 1b is shown as it was disordered in the C5 structure, but clearly ordered in the C5-CVF structure, and this is interesting for functional reasons as Low and Ogata 1999 showed that deletion of residues neighboring this hairpin reduce CP convertase activity significantly.
The maps used for fitting were usually two-fold averaged 2mFo-DFc maps, and therefore of better quality, and we now show four examples of such maps from the C5-CVF interface in the suppl. fig.  2 panels E-H to convince the reader that we are able to model conformational changes in loop regions and that for many side chains we are able to place at least the C-beta atom in density at a contour level of 1 sigma at the C5-CVF interface. As described in the manuscript, the two-fold noncrystallographic symmetry was also implemented during refinement with tight NCS restraints, and for large parts of the structure we even used four-fold averaged maps coming from multiplecrystal averaging (two complexes in both the C5-CVF and the SSL7-C5-CVF structure). Concerning the C5-CVF interactions, we do not anywhere describe or discuss detailed interactions, and in the revised manuscript we often use "putative", "apparent" or similar terms when we describe/discuss regions involved in intermolecular interactions in order remind the reader about the uncertainty due to the low resolution.
Concerning the Ramachandran plot quality, this is highly resolution dependent. For comparison C3c from the entry 3NMS (Geisbrecht, 2010) determined at 4.1 Å resolution has 78-21-1% in the Ramachandran plot, and C3b from the 2WIN entry (Gros, 2009) determined at 3.9 Å resolution has 77-22-1%. Therefore considering the resolution, our Ramachandran plot statistics of 74-25-1% and 73-27-1% are very normal at the even lower resolution.
Finally, concerning the general argument against publishing low-resolution structures in highranking journals. Even the most prominent journals routinely publish EM reconstructions of large macromolecular complexes, and almost all of these have a lower resolution than the 4.3 Å presented here. Such low resolution structures are valuable and provide crucial functional insight, especially when partial high-resolution structures are used as starting point for the interpretation of EM reconstructions and crystallographic electron densities at low resolution, a prominent example is the numerous EM studies of ribosomes published over the last 10 years. This is exactly also the case in this MS, where structures of all components (C5, SSL7, and CVF) are known at much better resolution. If this was not the case, and our structures were based entirely on 4.3 Å diffraction data, one would have to be considerably more skeptical than in the current case. Additionally, our structure is the only available giving any structural detail concerning convertase-substrate interactions, not even low-resolution EM studies has so far provided an insight into this important aspect of complement activation. The C3b-Bb-SCIN structure gave a glimpse of these interactions at the MG4-MG5 interface at 3.9 Å resolution, but at the time they were published, it was not certain that they were not just crystal packing artifacts. In an ideal situation one would have a structure with a resolution of at least 2.6 Å resolution of a fully assembled convertase in complex with a substrate, but that might be very challenging to achieve. Important results in structural biology very often progress from a low resolution structure to a more perfect high resolution structure. Response: the origin of the CVF model used for molecular replacement is clearly described "The C5-CVF structure was solved using the C5 domains C5d, CUB and MG8 (residue 932-1514), and CVF from the CVFB structure (RCSB entry 3HRZ) with the C-terminal C345C domain omitted as two independent search models.". There is a structure of apo-CVF at the RCSB determined at a resolution of 2.6 Å, but this is very similar to the structure of CVF from the CVF-B complex that we used, that was determined at 2.2 Å, and we therefore omitted comparison with this structure in the original MS. Likewise, we did not compare CVF bound to C5 with all the structures of C3b in the RCSB data base. However, the comment made by the reviewer is relevant, and we now compare CVF from the C5 complex to both bound and unbound CVF by writing in the revised MS:
"Complex formation with C5 has little influence on the conformation of CVF compared to either free CVF (Krishnan et al, 2009) or CVF in complex with fB (Janssen et al, 2009) . Only the Cterminal C345C and the CUB domains have a slightly variable orientation relative to the remaining CVF molecule, but these discrepancies may easily be caused by differences in crystal packing interactions and the presence of factor B in the CVFB complex, and neither of the two domains are in direct contact with C5. Likewise, the conformation of C5-bound CVF is also close to that of C3b alone (Supplementary Figure S4) or C3b Concerning C3b, it is clear from the text above and suppl. figure 4 that the conformations of C3b and CVF bound to C5 is very similar. Concerning C4b, we donít know the structure, but there are strong functional arguments for that it must be very similar to C3b, and we also rationalize a number of experimental observation concerning the CP convertases based on this assumption and our own structure, further supporting the similarity of C3b/C4b.
Referee #2 (Remarks to the Author): .
Response: We understand the concerns of the reviewer, but do not want to include Kd values in the abstract. Instead we have modified the abstract to read: "Complement acts as a danger sensing system in the innate immune system, and its activation initiates a strong inflammatory response and cleavage of the proteins C3 and C5 by proteolytic enzymes, the convertases. These contain a noncatalytic substrate contacting subunit (C3b or C4b) in complex with a protease subunit (Bb or C2a)." We hope this is sufficient to avoid the reader getting the impression that only C3b/C4b contributes to substrate affinity. Response: We did include the SSL7-C5-CVF structure in order to further substantiate that efficient SSL7 inhibition of C5 cleavage requires IgA Fc to exert steric hindrance upon convertase binding.
This was in our recent PNAS paper supported by a model of the C5-convertase complex based on the C3b-Bb-SCIN structure, but with the SSL7-C5-CVF structure at hand, we can now with much higher confidence claim that IgA mediated steric hindrance is the determinant, and we can more reliably pinpoint the areas of the convertase that will be clashing with IgA if the convertase attempts to bind an IgA-SSL7-C5 complex. As both reviewer 2 and 3 suggest to emphasize the SSL7-C5-CVF structure more we now mention the structure in the abstract. We have also reorganized the text and figures, such that the SSL7 bound structure is described rather early in the results section, the original figure 4 showing the structure is now figure 2 (meaning that original figures 2 and 3 are now 3 and 4). Response: We have rewritten the section and now provide more detailed suggestion for exploiting C5 related structural information to selectively block e.g. MAC assembly.
Referee 2:Minor points: P.11 last paragraph: C4b does not recognize C5.
Response: We believe that the reviewer refers to that C4b has to part of the CP C5 convertase to recognize C5, and we therefore now write "This is in apparent conflict with our hypothesis that C4b as a subunit of the CP C5 convertase and CVF will recognize C5 in a similar manner"
Referee 2: Fig. 1A Inclusion of the "C" -e.g. C4bC2a would be helpful for readers less familiar with complement.
Response: We agree with the reviewer that the complement nomenclature is very compact for readers outside of the field, but on the other hand it is the standard within the field, and as such we want to maintain it, and therefore describe it carefully. We therefore now write in the introduction "C4b combines with C2 and subsequent cleavage of C2 to C2a results in generation of the LP/CP C3 convertase C4b2a (C4b2a is the widely used short hand nomenclature for the C4b-C2a complex in the complement field, and similar nomenclature is used for remaining complexes in the following)." Additionally, in the legend to Fig. 1a , we now write: "Abbreviations for the complexes: C4b2a = C4b-C2a complex; C3bBb = C3b-Bb complex; C4b2a3b = C4b-C2a-C3b complex; C3bBb3b = C3b-Bb-C3b complex; CVFBb = CVF-Bb complex; C3(H2O)Bb = C3(H2O)-Bb complex."
Referee 2. Typo in table 1.
Response: fixed
Referee #3 (Remarks to the Author):
Ref: EMBOJ-2010-75782 Title: Substrate recognition by complement convertases revealed in the C5-cobra venom factor complex
